Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human Study to Evaluate the Safety, Feasibility and Tolerability of Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) in Patients With Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Cell Transplantation (alloHCT)

NCT05993611 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT05993611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05993611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human Study to Evaluate the Safety, Feasibility and Tolerability of Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) in Patients With Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Cell Transplantation (alloHCT)
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Suspended
Start date
February 19, 2024
Completion date
May 21, 2028
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft versus host disease, hematologic and lymphocytic disorder, steroid refractory graft versus host disease